This case is of great interest to our firm, as we are representing a number of GranuFlo recall clients who have put forth similar allegations in their lawsuits.
New York, New York (PRWEB) July 08, 2014
GranuFlo lawsuits (http://www.thegranuflolawsuit.com) filed in the wake of the 2012 GranuFlo and NaturaLyte dialysis concentrate recall continue to move forward in courts throughout the U.S., Bernstein Liebhard LLP reports. According to court documents filed on July 3rd, a federal judge in Missouri has remanded a GranuFlo and NaturaLyte lawsuit filed on behalf of 48 plaintiffs to the Circuit Court for the City of St. Louis. In doing so, U.S. District Judge Stephen M. Limbaugh Jr. of the Eastern District of Missouri rejected a number of insertions put forth by the defendants, including an argument that certain plaintiffs were fraudulently joined because their claims were time-barred. (McGee, et al. v. Fresenius Medical Care North America Inc., et al., No. 4:14-967)
“This case is of great interest to our firm, as we are representing a number of GranuFlo recall clients who have put forth similar allegations in their lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who allegedly suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects within 72 hours of a dialysis treatment involving the use of GranuFlo of NaturaLyte.
GranuFlo and NaturaLyte recall
Both GranuFlo and NaturaLyte are manufactured by Fresenius Medical Care, and are administered to kidney failure patients to remove toxins from the blood during dialysis treatments. In March 2012, Fresenius issued an Urgent Product Notification for both products that warned of dosage issues that could cause dialysis patients to suffer serious and catastrophic heart side effects. The U.S. Food & Drug Administration (FDA) ultimately granted Class I recall status to the Urgent Product Notification, which indicates GranuFlo and NaturaLyte posed a risk of serious injury and death.
Court records indicate that more than 1,860 GranuFlo lawsuits are now pending in a multidistrict litigation underway in the U.S. District Court, District of Massachusetts. All of the lawsuits similarly allege that Fresenius failed to provide adequate warnings regarding the risks associated with GranuFlo and NaturaLyte, and that the company continued to aggressively market the products even once it became aware of those risks. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
In additional to the cases pending in the federal multidistrict litigation, additional GranuFlo and NaturaLyte lawsuits have been consolidated on the state level in the Massachusetts’ Middlesex County Superior Court. (In re: Consolidated Fresenius Cases, No. MICV2013-03400-O).
Individuals who allegedly suffered life-threatening cardiac events related to the GranuFlo and NaturaLyte recall may be entitled to compensation for their injury-related damages. To learn more about filing a GranuFlo lawsuit, please visit Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP